Table 1.
Comparison of presenting features and treatments between study participants and non-participants
| Participants (N=90) | Non-Participants (N=37) | P value | |
|---|---|---|---|
| Age at diagnosis, Median (range) | 16 (4-22) | 15 (6-20) | 0.3079 |
| Age at Ovarian transposition, Median (range) | 15 (4-24) | 14.5 (7-22) | 0.9364 |
| Race/Ethnicity (N, %) | 0.2277 | ||
| White | 77 (85.6) | 35 (94.6) | |
| Non-white | 13 (14.4) | 2 (5.4) | |
| Ovarian transposition (N, %) | 0.2804 | ||
| Yes | 49 (54.4) | 24 (64.9) | |
| No | 41 (45.6) | 13 (35.1) | |
| Pelvic radiation dose (N, %), cGy | 0.2932 | ||
| ≤ 1500 | 32 (36.8) | 9 (25.0) | |
| > 1500 | 55 (63.2) | 27 (75.0) | |
| Alkylating Agent Cyclophosphamide Equivalent Dose (N, %), mg/m2 | 0.5815 | ||
| 0 to <= 8000 | 45 (51.7) | 21 (58.3) | |
| 8000 to <= 12000 | 18 (20.7) | 7 (19.4) | |
| 12000 to <= 20000 | 20 (23.0) | 5 (13.9) | |
| > 20000 | 4 (4.6) | 3 (8.3) | |
| Median (range) | 8818.2 (1800.0-28980.0) | 8034.4 (2339.0-31625.9) | |
| Nitrogen mustard (N, %), mg/m2 | 3 (3.3) | 2 (5.4) | |
| Median (range) | 18.4 (18.1-36.7) | 20.7 (17.5-23.9) | 0.7728 |
| Procarbazine (N, %), mg/m2 | 65 | 31 | |
| Median (range) | 4433.3 (857.1-15633.3) | 4114.3 (714.3-17710.5) | 0.6779 |